ChatGPT in the Management of Chronic Rhinosinusitis with Nasal Polyps: Promising Support or Digital Illusion? Insights from a Multicenter Observational Study
Authors:
- Riccardo ManzellaRMRiccardo Manzella
- Angelo ImmordinoAngelo Immordino
- Cosimo GallettiCosimo Galletti
- Federica Giammona IndacoFIFederica Giammona Indaco
- Giovanna StiloGSGiovanna Stilo
- Giuliano MessinaGMGiuliano Messina
- Francesco LorussoFLFrancesco Lorusso
- Rosalia GarganoRGRosalia Gargano
- Silvia FrangipaneSFSilvia Frangipane
- Giorgia GiuntaGGGiorgia Giunta
- Diana MariutDMDiana Mariut
- Daniele PortelliDPDaniele Portelli
Open Access
- 25 June 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4501
Abstract
Background/Objective: Chronic rhinosinusitis with nasal polyps is a chronic inflammatory disease with a significant impact on quality of life and is frequently associated, from a pathogenetic perspective, with type 2 inflammation. The introduction of biologic therapies has marked a turning point in the management of severe forms of the disease, offering a valuable treatment option. However, selecting the most suitable biologic agent for a specific patient remains a clinical challenge. Artificial intelligence, and, in particular, ChatGPT, has recently been proposed as a potential tool to support medical decision-making and guide therapeutic choices. To evaluate the concordance between the therapeutic recommendations provided by ChatGPT and those of a multidisciplinary expert board in selecting the most appropriate biologic therapy for CRSwNP patients, based on the analysis of their phenotype and endotype. Methods: A multicenter observational cohort study was conducted. Clinical data from 286 patients with CRSwNP were analyzed. For each case, the therapeutic choice among Dupilumab, Mepolizumab, and Omalizumab was compared between the board and ChatGPT. Concordance rates and Cohen’s Kappa coefficient were calculated. Results: Overall concordance was 59.2%, with a Cohen’s Kappa coefficient of 0.116. Concordance by drug was 62.8% for Dupilumab, 26.5% for Mepolizumab, and 9.1% for Omalizumab. Patients presented with severe clinical profiles, with an average Nasal Polyp Score of 6.22 and an average SNOT-22 score of 64.5. Conclusions: This study demonstrates that, despite its substantial theoretical potential, ChatGPT is currently not a reliable tool for the autonomous selection of biological therapies in patients with CRSwNP. Further studies are necessary to enhance its reliability and integration into clinical practice.Keywords
Funding Information
- European Union–NextGenerationEU–MUR funds D.M. (737/2021)
This publication has 25 references indexed in Scilit:
- Mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experienceAmerican Journal of Otolaryngology, 2025
- ChatGPT versus clinician: challenging the diagnostic capabilities of artificial intelligence in dermatologyClinical and Experimental Dermatology, 2023
- Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experienceAmerican Journal of Otolaryngology, 2023
- Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polypsWorld Allergy Organization Journal, 2023
- The prognostic value of subjective nasal symptoms and SNOT-22 score in middle ear surgeryAmerican Journal of Otolaryngology, 2022
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Respiratory Medicine, 2021
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsJournal of Allergy and Clinical Immunology, 2020
- A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal PolyposisCurrent Allergy and Asthma Reports, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Cost-effectiveness and comparative effectiveness of biologic therapy for asthmaAnnals of Allergy, Asthma & Immunology, 2019